Rubius Therapeutics competitorsClear all

Rubius Therapeutics's top competitors include Kymera Therapeutics and Atara Biotherapeutics.

Save Comparison	Rubius Therapeutics Rubius is developing a new class of drugs, Red-Cell Therapeutics™.	Kymera Therapeutics Kymera Therapeutics is a biotechnology company aimed to create medicines for patients with previously untreatable diseases.	Atara Biotherapeutics Atara Biotherapeutics is a drug development company focused on developing innovative therapies for patients with debilitating diseases.
Founding Date	Founding Date 2013	Founding Date 2017	Founding Date 2012
Type	Type Public	Type Private	Type Public
Tags	Tags Healthcare biotech drug development therapy	Tags Healthcare biotech drug development therapy	Tags Healthcare biotech drug development therapy
Locations	Locations Cambridge, US HQ Smithfield, US	Locations Cambridge, US HQ	Locations South San Francisco, US HQ Zug, CH Aurora, US New York, US Thousand Oaks, US
Employees	Employees 17423% increase	Employees 737% increase	Employees 39326% increase
Valuation ($)	Valuation ($) 767.2 m	Valuation ($) N/A	Valuation ($) 1.5 b
Twitter followers	Twitter followers 1 k	Twitter followers 1.8 k	Twitter followers 1.2 k
Number of tweets (last 30 days)	Number of tweets (last 30 days) 11	Number of tweets (last 30 days) 7	Number of tweets (last 30 days) 4
Average likes per tweet (last 30 days)	Average likes per tweet (last 30 days) 5.3	Average likes per tweet (last 30 days) 12.6	Average likes per tweet (last 30 days) 11.5
Percentage of tweets with engagement (last 30 days)	Percentage of tweets with engagement (last 30 days) 100%	Percentage of tweets with engagement (last 30 days) 100%	Percentage of tweets with engagement (last 30 days) 100%
Alexa Website Rank	Alexa Website Rank 339837	Alexa Website Rank 400507	Alexa Website Rank 238554
Financial
Net income	Net income ($163.5m) (FY, 2019)	Net income N/A	Net income ($291m) (FY, 2019)
Funding
Total funding raised	Total funding raised $ 245m	Total funding raised $ 197m	Total funding raised $ 61.8m